Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
Status:
Terminated
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and
sustained activity has been observed in advanced lung cancer. Ablation may stimulate the
immune system by exposing new tumor antigens. Since tumors that express PD-L1 may be more
likely to respond to nivolumab, if ablation increases PD-L1 expression (which has not been
studied) this treatment may enhance the activity of nivolumab at both the treated site and in
other, non-treated, tumors. Ablation is already an FDA approved treatment for cancer.
Nivolumab was recently FDA approved for second line treatment of advanced squamous cell
NSCLC. The goal of the study will be to determine if the combination of nivolumab and
ablation has higher systemic activity than previously reported with nivolumab alone.